Back to top
more

Lexicon Pharmaceuticals (LXRX)

(Delayed Data from NSDQ)

$1.77 USD

1.77
1,847,436

-0.07 (-3.80%)

Updated May 17, 2024 04:00 PM ET

After-Market: $1.77 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for LXRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Lexicon Pharmaceuticals, Inc. [LXRX]

Reports for Purchase

Showing records 141 - 160 ( 393 total )

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 141

05/05/2017

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 142

05/04/2017

Company Report

Pages: 2

Q1 Update - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 143

05/03/2017

Company Report

Pages: 7

Q1 Update Key Efficacy Data from Secondary Endpoints from InTandem1 Expected This Month.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 144

05/03/2017

Company Report

Pages: 6

1Q17: Early Xermelo Launch Efforts Look Promising; Additional Sota Readouts Coming Soon

Provider: H.C. Wainwright & Co., Inc.

Analyst: DEEPAK S

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 145

05/02/2017

Daily Note

Pages: 46

May and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 146

04/28/2017

Daily Note

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 1

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 147

04/24/2017

Daily Note

Pages: 11

Best Ideas List: Update

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 148

04/21/2017

Industry Report

Pages: 6

The Week Ahead in Life Sciences: Upcoming Events for the Week of April 24

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 149

04/07/2017

Industry Report

Pages: 5

The Week Ahead in Life Sciences Upcoming Events for the Week of April 10.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 150

04/04/2017

Daily Note

Pages: 46

April and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 151

03/20/2017

Industry Report

Pages: 8

Best Ideas List: Update

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 152

03/08/2017

Daily Note

Pages: 42

March and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 153

03/07/2017

Company Report

Pages: 7

Q4/FY16 Update; Path forward for Sotagliflozin in Type 1 Diabetes Could be Defined this Year; Reiterate OUTPERFORM and $38 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 154

03/06/2017

Company Report

Pages: 2

Xermelo Brings New Chapter - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 155

03/06/2017

Company Report

Pages: 6

4Q16: Focusing on Xermelo Launch and Sota Readouts in 2017

Provider: H.C. Wainwright & Co., Inc.

Analyst: DEEPAK S

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 156

03/01/2017

Company Report

Pages: 7

XERMELO Approved for Carcinoid Syndrome with Impending U.S. Launch; Reiterate OUTPERFORM and Raising PT to $38 on FDA Approval

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 157

03/01/2017

Company Report

Pages: 6

FDA Approves Xermelo, Launch Expected Within the Week; Raising PT to $27 From $26

Provider: H.C. Wainwright & Co., Inc.

Analyst: DEEPAK S

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 158

02/24/2017

Industry Report

Pages: 5

The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 27

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 159

02/23/2017

Daily Note

Pages: 7

Best Ideas List: Update

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 160

02/10/2017

Daily Note

Pages: 5

The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 13

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party